By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Pressure BioSciences said today that a Nasdaq panel has agreed to allow it to remain listed on the exchange while it tries to regain compliance with two listing requirements.

Pressure Bio said that the Nasdaq Listing Qualifications Panel notified the firm on March 7 that it is extending the deadline to regain compliance with a listing requirement calling for at least $2.5 million in stockholder equity. Pressure Bio will now have until March 23 to regain compliance.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Science speaks with the University of Michigan's Jedidiah Carlson, who has tracked population genetic discussions at white nationalist sites.

Gene therapies could qualify for a faster US Food and Drug Administration approval process, according to Stat News.

NPR reports that the US House of Representatives has passed a bill to enable terminally ill patients access to experimental drugs.

In Genome Research this week: inversion variants mapped in human, non-human primate genomes; transcriptome profiling of maize, sorghum; and more.